Work Here?
Scorpion Therapeutics
Work Here?
Develops precision oncology drugs through partnerships
Scorpion Therapeutics
Work Here?
Develops precision oncology drugs through partnerships
Overview
Scorpion Therapeutics develops precision oncology drugs that target validated cancer drivers. It designs therapies with high target selectivity and favorable pharmacology, using biology, chemistry, proteomics, and computation, then partners with large pharmaceutical companies to fund and scale development. It differentiates itself through a target-driven science approach and strategic collaborations with milestone and royalty terms. The goal is to deliver fast, precise, and potent cancer treatments and bring them to patients worldwide through partnerships.
About Scorpion Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
Get referred to Scorpion Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Lilly’s up-to-$2.5 billion payment validated Scorpion’s science and de-risked its platform.
- Pierre Fabre’s earlier EGFR deal showed Scorpion could monetize assets before commercialization.
- Antares launched with $177 million in June 2025, extending Scorpion’s team and discovery engine.
What critics are saying
- Lilly’s January 2025 deal stripped Scorpion’s lead program, leaving a hollowed-out shell.
- Antares inherited employees and assets, so Scorpion’s standalone employer identity ended by 2025.
- Without STX-478, Scorpion faces existential irrelevance if remaining assets never reach clinic.
What makes Scorpion Therapeutics unique
- Scorpion’s chemistry platform produced STX-478, a mutant-selective PI3Kα inhibitor Lilly bought in January 2025.
- Its non-PI3K discovery engine spun out as Antares in June 2025, preserving management and methods.
- Scorpion built differentiation around chemical proteomics, machine learning, and previously undruggable cancer targets.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$420M
Above
Industry Average
Funded Over
4 Rounds
Lightspeed Venture PartnersGrowth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -20%2 year growth
↑ 0%The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...
In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.
Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding
Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.
There are no jobs for Scorpion Therapeutics right now.
Find jobs on Simplify and start your career today
About Scorpion Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
There are no jobs for Scorpion Therapeutics right now.
Find jobs on Simplify and start your career today